Phio Pharmaceuticals (PHIO) Non-Current Debt (2020)

Phio Pharmaceuticals' (PHIO) quarterly Non-Current Debt came in at $231000.0 in Q4 2020, little changed on a QoQ basis from $231000.0 in Q3 2020.

Phio Pharmaceuticals (PHIO) Non-Current Debt (2020) Analysis & Trends

Phio Pharmaceuticals (PHIO) has 1 years of Non-Current Debt data on file, last reported at $231000.0 in Q4 2020.

Quarterly Non-Current Debt changed N/A year-over-year to $231000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $231000.0 (changed N/A YoY) and the FY2020 annual result came in at $231000.0, changed N/A from the prior year.
Non-Current Debt held at $231000.0 in Q4 2020, from $231000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $231000.0 in Q2 2020 to a low of $231000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.88 Bn	132.03 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.62 Bn	78.62 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.28 Bn	60.10 Bn	1.37 Bn	-
4	Moderna	61.39 Bn	56.25 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.37 Bn	28.06 Bn	992.69 Mn	-
7	BioNTech SE	28.76 Bn	10.37 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	8.96 Bn
10	Phio Pharmaceuticals	13.96 Mn	13.96 Mn	-	-

Download Data